Active Ingredient History

  • Now
Satraplatin is a platinum-based antineoplastic agent that was under investigation as a treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration. First mentioned in the medical literature in 1993, satraplatin is the first orally active platinum-based chemotherapeutic drug; other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.   Wikipedia

More Chemistry
bis-acetatoamminedichlorocyclohexylamine platinum(iv) | bms 182751 | bmy 45594 | cabazitaxel, docetaxel, mitoxantrone or satraplatin | jm216 | jm 216 | jm-216 | platinum, bis(acetato-o)amminedichloro(cyclohexanamine)-, (oc-6-43)- | satraplatin | trans,cis,cis-bis(acetato)amminecyclohexylaminedichloroplatinum(iv)


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue